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Epstein-Barr virus (EBV) SM protein is an essential nuclear shuttling protein expressed by EBV early
during the lytic phase of replication. SM acts to increase EBV lytic gene expression by binding EBV mRNAs
and enhancing accumulation of the majority of EBV lytic cycle mRNAs. SM increases target mRNA stability
and nuclear export, in addition to modulating RNA splicing. SM and its homologs in other herpesvirus have
been hypothesized to function in part by binding viral RNAs and recruiting cellular export factors. Although
activation of gene expression by SM is gene specific, it is unknown whether SM binds to mRNA in a specific
manner or whether its RNA binding is target independent. SM-mRNA complexes were isolated from EBV-
infected B-lymphocyte cell lines induced to permit lytic EBV replication, and a quantitative measurement of
mRNAs corresponding to all known EBV open reading frames was performed by real-time quantitative reverse
transcription-PCR. The results showed that although SM has broad RNA binding properties, there is a clear
hierarchy of affinities among EBV mRNAs with respect to SM complex formation. In vitro binding assays with
two of the most highly SM-associated transcripts suggested that SM binds preferentially to specific sequences
or structures present in noncoding regions of some EBV mRNAs. Furthermore, the presence of these sequences
conferred responsiveness to SM. These data are consistent with a mechanism of action similar to that of
hnRNPs, which exert sequence-specific effects on gene expression despite having multiple degenerate consen-
sus binding sites common to a large number of RNAs.
Epstein-Barr virus (EBV) SM is an RNA binding protein
that is essential for lytic EBV replication (1, 5, 6, 8, 14, 15, 17,
33–35, 42). The SM gene is homologous to immediate-early or
early genes expressed by several other human and animal her-
pesviruses, including those encoding herpes simplex virus type
1 (HSV-1) ICP27, human cytomegalovirus (HCMV) UL69,
varicella-zoster virus open reading frame 4 (ORF4) protein,
and Kaposi’s sarcoma-associated herpesvirus (KSHV) ORF57
protein/Mta (2, 24, 27, 30, 36, 47). These proteins are multi-
functional and function as transcriptional and posttranscrip-
tional regulators of gene expression. One of the major roles of
SM is to enhance EBV gene expression by increasing the
accumulation of lytic EBV transcripts (5, 21, 39). In experi-
ments performed with cells infected with recombinant EBV
with SM deleted, exogenous expression of SM increased the
expression of more than 50% of lytic EBV transcripts (15).
Most of these SM-responsive transcripts accumulate poorly in
the absence of SM. The dependence of these mRNAs on SM
is multifactorial, as lytic EBV DNA replication also requires
SM, primarily due to SM-enhanced expression of EBV DNA
polymerase and primase proteins (15). Thus, SM may stimu-
late lytic EBV gene expression indirectly, by enhancing lytic
EBV replication, as well as by having direct effects on target
mRNAs. SM is thought to bind to EBV mRNAs in the nucleus
and to enhance mRNA export by recruiting cellular export
factors (3, 7, 18). In addition, SM enhances the nuclear accu-
mulation of target mRNAs, suggesting that SM also increases
RNA stability (28, 35). SM binds to mRNA targets in vivo,
which can be coimmunoprecipitated with SM (33). SM can be
UV cross-linked to RNA in vitro, and direct contact of SM
with RNA is suggested by transfer of radioactive label from
RNA to SM protein (46). An arginine-rich motif in SM has
been shown to bind RNA in vitro, and SM mutants with this
motif deleted are defective in RNA binding (17).
SM exhibits some degree of preferential cross-linking to
RNA targets in vitro, and several lines of evidence indicate
that SM exerts gene-specific effects. In reporter assays, SM is
particularly active against certain targets, such as chlorampheni-
col acetyltransferase (33, 35). In addition, as noted above, SM is
required for the expression of approximately 60% of EBV lytic
genes, but the remainder of EBV lytic genes are expressed
efficiently in the absence of SM (15). Further, SM acts as an
alternative splicing factor, directing donor splice site usage to
a specific alternate 5 splice site (46). While these findings
suggest that SM may preferentially associate with sequence- or
structure-based elements present in some mRNAs, it is also
possible that SM binds mRNAs nonspecifically but has differ-
ent effects on various targets. For example, it is possible that
some EBV mRNAs possess constitutive transport elements
that utilize cellular nuclear export pathways, rendering SM
superfluous. Similarly, other mRNAs may be unstable and
require SM to bind and stabilize them or protect them from
degradation in order to accumulate efficiently. Thus, regardless
of the mechanism of action of SM, it is possible that tran-
script-specific effects of SM may be unrelated to transcript-
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specific binding. In fact, previous experiments have shown
that mRNAs transcribed from both SM-responsive and non-
SM-responsive transfected genes are immunoprecipitated
equally well with SM (33).
Currently, it is unclear whether SM or its homologs in other
herpesviruses associate preferentially with specific transcripts
in vivo. In this study, we performed SM immunoprecipitations
(IPs) from EBV-infected B lymphocytes and analyzed the
RNA in the immunoprecipitates with a quantitative reverse
transcription (RT)-PCR (qRT-PCR) microarray. These exper-
iments demonstrated that SM associates preferentially with
specific EBV mRNAs and that SM binds to specific portions of
these mRNAs in vitro.
MATERIALS AND METHODS
Plasmids and cell lines. EBV BFRF3 DNA from the 5 untranslated region
(UTR) to the cleavage and polyadenylation signal and antisense BFRF3 were
cloned by high-fidelity PCR amplification of B95-8 DNA using AccuPrime Pfx
DNA Polymerase (Invitrogen). The BFRF3 clone included nucleotides from
B95-8 EBV genome positions 49056 to 49806 (accession number NC00705) using
primers flanking the entire BFRF3 gene, including the 5 and 3 UTRs. Restric-
tion sites were incorporated into the PCR primers, and PCR products were
directionally cloned into the HindIII and EcoRV sites of pcDNA3 (Invitrogen).
The orientations of the inserts were determined by restriction enzyme digestion
and confirmed by DNA sequencing.
Subclones of BFRF3, each encompassing approximately one-fourth of the
gene extending from the 5 UTR to 20 nucleotides (nt) downstream of the
cleavage and polyadenylation signal of BFRF3, were also constructed by PCR
amplification. PCR was performed using specific 5 and 3 primers. The PCR
products ranged between 186 and 196 nt in length. Each cloned PCR product was
screened by restriction digestion and confirmed by DNA sequencing.
The PCR primers were as follows: BFRF3 5 Q1HindIII, 5-CTGAAAGC
TTTATTTAACTTTGCGGACAGAGG-3 (nt 49056 to 49078); BFRF3 3
Q1EcoRV, 5-TCAGGATATCGTTGGGCTTGGGCAGCCGGCGTG3- (nt
49223 to 49243); BFRF3 5 Q2HindIII, 5-CTGAAAGCTTCAAGCCCACCCTC
CAG-3 (nt 49236 to 49251); BFRF3 3 Q2EcoRV, 5-TCAGGATATCGGCACC
CCAAAAGTCCTCTGCAC-3 (nt 49399 to 49421); BFRF3 5 Q3HindIII, 5-CT
GAAAGCTTTCGGCGCCAACGCGCCATAGACAAG-3 (nt 49422 to 49446);
BFRF3 3 Q3EcoRV, 5-TCAGGATATCGATGAAGAAACAGAGGGGGTC-3
(nt 49596 to 49616); BFRF3 5 Q4HindIII, 5-CTGAAAGCTTTCATCTATTAG
CAGCCTC-3 (nt 49612 to 49629); BFRF3 3 Q4EcoRV, 5-TCAGGATATCAG
TTTTTGTATCTGTAATTG-3 (nt 49787 to 49806); BFRF3 5 EcoRV, 5-TCAG
GGATATCTATTTAACTTTGCGGACAGAG-3 (nt 49056 to 49077); BFRF3 3
HindIII, 5-CTGAAAGCTTAGTTTTTGTATCTGTAATTG-3 (nt 49787 to
49806); BDLF3 5 Q1 HindIII, 5-CTGAAAGCTTTATAAAAGAGGCCGGGA
G-3 (nt 118816 to 118799); BDLF3 3 Q1 EcoRV, 5-TCAGGATATCGATGCC
GACGGTGATGG-3 (nt 118990 to 119006); BDLF3 5 Q2 HindIII, 5-CTGAA
AGCTTGGGTCCTAGCACAAACCAG-3 (nt 119007 to 119025); BDLF3 3 Q2
EcoRV, 5-TCAGGATATCTCCTGTTCCGGCCTCGGTG-3 (nt 119193 to
119210); BDLF3 5 Q3 HindIII, 5-CTGAAAGCTTAACCTCCACGGGTGTGA
CTAG-3 (nt 119211 to 119231); BDLF3 3 Q3 EcoRV, 5-TCAGGATATCCCA
GAGAGGAAGACCGTAAG-3 (nt 119390 to 119409); BDLF3 5 Q4 HindIII,
5-CTGAAAGCTTACACTGGTGTTTGTGGGGC-3 (nt 119410 to 119428); and
BDLF3 3 Q4 EcoRV, 5-TCAGGATATCTTCAAGAAAGTTCATTAAAC-3
(nt 119568 to 119587).
Cell lines. P3HR1 is a Burkitt lymphoma cell line infected with EBV type 2
(31), and B95-8 is a marmoset B-cell line transformed by EBV type 1 (26). Both
cell lines were transfected and selected to stably express a fusion protein con-
taining the BZLF1 transactivator of early lytic cycle replication fused to the
hormone domain of the estrogen receptor, which, in the presence of 4-hydroxyta-
moxifen (4-HT), allows the functional release of BZLF1, inducing lytic EBV
replication (19, 45). The P3HR1-ZHT and B958-ZHT cell lines were propagated
in RPMI supplemented with 10% fetal bovine serum (HyCLone), 0.8 mg/ml
G418 (AG Scientific), and GlutaMax (Invitrogen). Cos7 cells are African green
monkey kidney fibroblast cells transformed with a mutant simian virus 40 (13).
These cells were maintained in Dulbecco’s modified Eagle medium supple-
mented with 10% fetal bovine serum and L-glutamine. All cells were grown at
37°C in 5% CO2.
IP and RNA isolation. Lytic replication was induced in 1.8  107 P3HR1-ZHT
or B958-ZHT cells at 5  105 cells/ml by adding 100 nM 4-HT to the cell growth
medium. Cells were harvested 48 h after the addition of 4-HT and lysed in
ice-cold IP lysis buffer (Tris-buffered saline [pH 7.4], 1% Triton X-100, and
protease inhibitor cocktail; Sigma-Aldrich) prepared with RNase-free reagents.
All subsequent steps were performed at 4°C. The cells were incubated in lysis
buffer for 10 min on ice with frequent mixing and were sonicated to ensure
maximum lysis. The lysed-cell suspension was centrifuged for 10 min at 105  g.
The supernatant was transferred to fresh tubes and precleared by incubation with
0.8 g of normal rabbit immunoglobulin G (Bethyl) per 106 cells, followed by
incubation with protein A-conjugated agarose beads (Sigma) for 2 h. The cleared
supernatants were then immunoprecipitated with either preimmune (PI) serum
or rabbit polyclonal anti-SM antibody (0.8 g antibody per 106 cells) overnight,
followed by incubation with protein A-agarose beads for 2 h. The beads were
washed four times in IP wash buffer (500 mM NaCl, 25 mM Tris, 27 mM KCl, 1%
NP-40 [pH 7.4]). Coimmunoprecipitated RNA was isolated from the immuno-
precipitates using RNA-bee (Teltest), Glycoblue (Ambion), and RNeasy col-
umns (Qiagen) with an on-column DNase treatment (Qiagen) and eluted with
RNase-free Tris-EDTA buffer. RNA was quantitated by spectrophotometry.
cDNA microarray and analysis. Real-time qRT-PCR arrays containing PCR
primers targeting all ORFs of the EBV genome were designed and performed as
previously described (23). RNA used in the microarray analysis was coimmuno-
precipitated and purified as described above. RT of RNA was performed with
reverse transcriptase (Invitrogen), 2 mM deoxyribonucleoside triphosphates, 2.5
mM MgCl2, RNAsin (Applied Biosystems Inc.), and random hexamers. The
conditions for RT were 42°C for 45 min, 52°C for 30 min, and 70°C for 10 min.
Following RT, the removal of excess RNA was performed by incubation of each
RT reaction mixture with 1 U of RNase H at 37°C. Real-time PCR was per-
formed in triplicate for each sample with SYBR green PCR mix (Applied
Biosystems) using universal cycling conditions (29). Raw cycle threshold (CT)
values were determined by threshold analysis and used directly to compare
differences.
Northern blotting. P3HR1-ZHT and B958-ZHT cells were induced to permit
lytic replication by incubating the cells at 5  105 cells/ml in 100 nM 4-HT; 107
cells were harvested for RNA at 0 and 48 h after induction, and RNA coimmu-
noprecipitated with SM was isolated as described above. RNA samples were
electrophoresed in a 1% denaturing formaldehyde agarose gel, transferred to a
nylon membrane (Zeta Probe; Bio-Rad), and UV cross-linked to the membrane.
Gene-specific probes were generated by PCR amplification, gel purification, and
random-primer labeling with [-32P]dCTP. The probes were hybridized to blots
overnight at 65°C, washed, and exposed to film and a phosphorimager screen for
quantification by ImageQuant software (GE Healthcare).
In vitro photo-cross-linking and RNA label transfer assay. Cos7 cells were
transfected with empty-vector plasmid (pcDNA3; Invitrogen) or SM expression
vector DNA (35) using Lipofectamine Plus (Invitrogen) in 100-mm dishes with
6 g of DNA per transfection dish, according to the manufacturer’s protocol.
The cells were harvested 48 h after transfection. The cells were washed with
warm Dulbecco’s modified Eagle’s medium-10% fetal bovine serum, gently
scraped off, and pelleted by centrifugation at 20°C for 5 min at 900  g. The cells
were lysed by resuspending the pellets in twice the pellet volume of ice-cold lysis
buffer (20 mM HEPES [pH 7.9], 10 mM NaCl, 10% glycerol, 3 mM MgCl2, 0.1%
NP-40, 0.2 mM EDTA, 0.4 mM phenylmethylsulfonyl fluoride, 1 mM dithiothre-
itol, and eukaryotic protease inhibitor cocktail ) and incubating the suspension
at 4°C for 15 min with frequent gentle mixing. The lysed-cell suspensions were
centrifuged at 4°C for 5 min at 15,000  g. The cleared supernatants were
transferred to a fresh tube, and high-salt buffer (20 mM HEPES [pH 7.9], 400
mM KCl, 20% glycerol, 0.2 mM EDTA, 0.4 mM phenylmethlysulfonyl fluoride,
1 mM dithiothreitol, and protease inhibitor cocktail ) was added at one-third
the volume of the supernatant. Aliquots of protein extracts were snap-frozen and
stored at 80°C.
RNAs were synthesized using full-length BFRF3, BFRF3 subclones, or anti-
sense BFRF3 plasmid DNAs, previously linearized with EcoRV, in the presence
of [-32P]rUTP (Perkin Elmer) and T7 RNA polymerase (NEB). Radioactively
labeled RNA transcripts were separated on denaturing urea-polyacrylamide gels,
and full-length transcripts were excised. Gel slices were crushed in a microcen-
trifuge tube, and RNA was eluted by incubation in 0.5 M NH4 acetate, 10 mM
Mg acetate, 0.1 mM EDTA, 0.1% sodium dodecyl sulfate (SDS) for 10 min at
65°C. The eluate was filtered twice and ethanol precipitated, and RNA was
resuspended in double-distilled H2O. The integrity of the purified labeled RNA
was verified by polyacrylamide gel electrophoresis (PAGE) and autoradiography,
and the radioactivity was quantitated by Cerenkov counting. UV cross-linking
was performed by incubating 2  106 cpm of each purified radiolabeled RNA
with 8 l of cell extract, 2 l of 20 mM magnesium acetate, 2 l of 10 mM ATP,
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2 l of 200 mM potassium glutamate, 2 l of 50 mM creatine phosphate, 1 l of
tRNA (1 mg/ml), and 1 l of RNAsin (Promega) in a total volume of 20 l. The
reaction mixtures were incubated at 30°C for 30 min in the lid of a microcentri-
fuge tube, and RNA-protein complexes were UV cross-linked on ice in a
Stratalinker (Stratagene) by exposure to 0.6 J/cm2. Samples were digested with
RNase A at 100 g/ml for 1 h at 37°C and immunoprecipitated using anti-SM
antibody and protein A-agarose beads. Purified proteins were separated on 10%
SDS-PAGE gels, followed by exposure on a phosphorimager screen and film.
RESULTS
Analysis of RNA isolated from SM immunoprecipitates
from Burkitt lymphoma cells revealed a hierarchy of RNA
affinities with SM. The presence of mRNA in association with
SM in immunoprecipitates from SM-transfected cells was pre-
viously demonstrated (33). Only three target transcripts were
measured, and no differences in binding to SM were observed,
although SM appeared to associate preferentially with newly
transcribed mRNA. The RNA in those studies was detected by
a sensitive RNase protection assay, and it was unclear whether
IP of SM from EBV-infected cells would yield associated RNA
in amounts adequate to be analyzed by qRT-PCR for all EBV
transcripts. We therefore utilized a cell line derived from the
Burkitt lymphoma cell line, P3HR1, that was engineered to
permit efficient, high-level lytic EBV replication and gene ex-
pression (45). The P3HR1-ZHT cell line contains a stably
transfected chimeric gene consisting of the Z immediate-early
transactivator fused to a 4-HT-specific hormone binding do-
main. These cells efficiently permit the resident EBV to enter
the lytic phase of EBV replication when 4-HT is added to the
growth medium. The strategy of the experiment is outlined in
Fig. 1. P3HR1-ZHT cells were induced or mock induced with
4-HT to permit EBV lytic replication and harvested 48 h after
induction. One fraction of the cells was immediately processed
to isolate total cellular RNA by lysis of the cell pellet in a
guanidinium isothiocyanate-phenol solution (RNA-Bee). The
remainder of the cells were lysed with detergent, in the pres-
ence of both protease and RNase inhibitors and immediately
divided into two aliquots, which were immunoprecipitated with
either anti-SM antibody or PI antibody. The immunoprecipi-
tates were then processed for isolation of any associated RNA
after the addition of dye-labeled glycogen as a carrier. These
RNAs were then analyzed by qRT-PCR using primers specific
for all known EBV ORFs. These analyses essentially provided
us with four quantitative measurements for each EBV mRNA:
(i) its abundance before induction of lytic replication, (ii) its
abundance 48 h after induction, (iii) its relative abundance in
SM immunoprecipitates 48 h after induction, and (iv) its rel-
ative abundance in control IPs performed with PI serum.
These measurements therefore allowed, for each mRNA, de-
termination of its level of induction during lytic replication, its
abundance relative to all EBV transcripts, and its relative
abundance in association with SM. In addition, the control IP
allowed correction for nonspecific IP of mRNA.
Raw CT values representing the relative abundances of tran-
scripts immunoprecipitated with SM versus those in the con-
trol immunoprecipitates were determined. The amount of
RNA in the SM IP was compared to that in the PI IP for each
ORF, and the relative enrichment by SM for each RNA target
was determined. There was a general enrichment for RNA in
the SM IP versus the control (PI IP), demonstrating that SM
bound significantly more RNA than the control. In induced
P3HR1-ZHT cells, approximately seven times more RNA was
immunoprecipitated by SM than in the control IP. This verified
the documented RNA binding activity of SM.
Using a linear regression model and the raw CT values for
the mRNA in SM IPs and PI IPs, a mean enrichment for all
EBV mRNAs in the SM IPs was calculated. This allowed a
ranking of all EBV mRNAs in terms of relative enrichment in
the SM IP (Fig. 2). The graph in Fig. 2 reveals the wide range
of affinities for SM, resulting in amounts of individual mRNAs
in the SM IP from 10-fold to 0.1-fold of the mean amount.
These findings therefore indicate that binding of individual
FIG. 1. Experimental design for quantitative analysis of RNA as-
sociation with SM in EBV-infected cells. Lymphoma cells were either
mock induced or induced to permit lytic EBV replication, and the cells
were divided into fractions for immediate RNA isolation (gray boxes)
or IP. After IP with either control or SM-specific antibody, RNA was
isolated from the immunoprecipitates. All RNA was reverse tran-
scribed, and the relative amount of each EBV transcript was measured
by qRT-PCR.
FIG. 2. Relative abundances of EBV mRNAs associated with SM.
CT values from qRT-PCR for each EBV transcript in the RNA isolated
from the SM IP were converted to the increase above or below the
mean enrichment for all transcripts (y axis). Enrichment for each
transcript was determined by comparison of its CT value in the SM IP
versus its CT value in the control immunoprecipitate. Each EBV
mRNA is represented by a bar on the x axis, and its enrichment relative
to the mean amount of all RNAs is represented on the y axis.
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EBV mRNAs is highly transcript dependent. Table 1 lists the
most highly SM-associated mRNAs, such as BFRF3, which was
10.6-fold more abundant than the mean, translating into 100-
fold greater abundance in the SM IP than the least abundant
mRNAs. The functions of the genes encoding the most highly
SM-associated mRNAs and their temporal classes are shown
in Table 2. There was no clear correlation between the tem-
poral class of the gene and association of its transcript with
SM, as both early and late lytic transcripts were enriched in SM
IPs. This outcome was not unexpected, since a time point after
induction at which most EBV mRNAs were actively tran-
scribed and the cells were still viable was chosen for harvest.
Affinity for SM does not correlate with transcript abun-
dance or level of induction. The level of transcript abundance
at 48 h after the induction of lytic replication varied consider-
ably among the 80 genes measured. Raw CT values for the
various transcripts varied by as much as 20 cycles (Fig. 3A).
Since almost all transcripts were enriched in the SM IP, albeit
to varying degrees, it was possible that SM bound mRNA
nonspecifically and that greater association with SM was
merely a function of transcript abundance. However, as shown
in Fig. 3B, the level of each transcript measured by qRT-PCR
in the total RNA from induced cells did not correlate with
whether a particular transcript was enriched in the SM IP,
demonstrating that relative association with SM is not merely
a function of the absolute amount of transcript present. This
finding is a critical aspect of the interpretation of the binding
FIG. 3. Relationship of SM association to transcript abundance
and level of gene induction. (A) The CT value for each EBV transcript
in the total RNA from induced P3HR1-ZHT cells is shown on the y
axis, with each EBV transcript plotted on the x axis, demonstrating the
range and distribution of transcript abundances. (B) Scatter plot of
the relative enrichment of each transcript in the SM IP relative to the
mean enrichment for all transcripts (CT; y axis) versus the abundance
of each transcript (CT; x axis). The area highlighted in gray contains
those transcripts highly enriched in the SM IP. (C) The level of induc-
tion of each EBV transcript during lytic replication (CT in induced
versus uninduced P3HR1-ZHT RNA) is represented on a logarithmic
y axis, and each EBV transcript is plotted on the x axis. (D) Scatter plot
of the relative enrichment of each transcript in the SM IP versus the
control IP (CT; y axis) versus the level of induction of each transcript
on a logarithmic x axis.
TABLE 1. EBV transcripts highly enriched in SM











BFRF3 29.79 24.15 5.64 3.4 10.6
BGLF5 32.05 26.78 5.27 3.3 9.8
BDLF3 34.51 29.67 4.84 3.1 8.6
BTRF1 32.84 28.20 4.64 2.7 6.5
BCRF1 36.88 32.87 4.01 2.6 6.1
BBRF3 27.79 23.04 4.75 2.3 4.9
BBRF2 36.58 33.05 3.53 2.1 4.3
BALF2 29.10 27.69 1.41 -0.8 0.6
a The CT values from qRT-PCR of RNAs isolated from control IPs and SM
IPs and the CT are shown for the transcripts most highly overrepresented in the
SM IP. The values for BALF2, a transcript that was underrepresented in the SM
IP, are also shown for comparison. Enrichment in the SM IP relative to the mean
enrichment for all mRNAs in the IP is shown as CT and as enrichment.
TABLE 2. Gene functions and classifications of
SM-associated transcripts
Gene Function Type
BFRF3 Viral capsid antigen Late
BGLF5 Host shutoff; alkaline exonuclease Early
BDLF3 Glycoprotein Late
BTRF1 Probable tegument protein Late
BCRF1 viral interleukin 10 Late
BBRF3 Glycoprotein M homolog Late
BBRF2 Viral tegument protein Late
BDLF2 Envelope glycoprotein Late
BNLF2b Unknown Early
BALF2 Single-stranded DNA binding protein Early
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data, since one would expect a correlation between the total
amount of each mRNA and the amount found in the SM IP if
SM was binding to all mRNAs nonspecifically.
As we have previously shown, SM may associate with nas-
cent transcripts (33), and therefore, the relative level of induc-
tion of a transcript may also play a role in how likely it is to be
associated with SM at a given time. The level of induction of
each transcript during lytic replication varied considerably
among the genes measured, ranging from zero to several hun-
dredfold (Fig. 3C). It was therefore relevant to assess whether
association with SM was more likely among highly induced
transcripts. This analysis demonstrated that the level of induc-
tion was not correlated with preferential association with SM,
suggesting that such association derives from sequence- or struc-
ture-related properties intrinsic to the transcripts (Fig. 3D).
In order to confirm the qRT-PCR findings, Northern blot-
ting of representative transcripts from both the total-RNA and
SM IPs was performed (Fig. 4). BFRF3, BBRF3 (highly SM
associated), and BALF2 (not highly SM associated) were cho-
sen for further analysis. BFRF3 is the small EBV capsid anti-
gen, BBRF3 is the EBV glycoprotein M homolog, and BALF2
is the single-stranded DNA binding protein. When the level of
expression was measured at 0 h and 48 h after the induction of
lytic replication, these genes were induced 15-, 5-, and 8-fold,
respectively. The level of each transcript in the SM IPs was
enriched approximately 70-, 27-, and 4-fold over the amounts
found in the control IP. The level of enrichment detected in
the SM IPs by Northern blotting therefore correlated well with
the amounts measured with the qRT-PCR array (approxi-
mately 75-, 35-, and 4-fold enrichment in the SM IPs) and
confirmed the differences in transcript affinity for SM mea-
sured by qRT-PCR.
Preferential association with SM of EBV transcripts from
B95-8 cells. Examination of SM binding to EBV transcripts
was also performed in B95-8 cells that had been stably trans-
fected with the Z-HT construct, permitting high-level lytic rep-
lication. In fact, lytic replication was extremely robust in these
cells, exceeding that observed in P3HR1-ZHT cells, with visi-
ble lysis of the majority of cells by 72 to 96 h after induction of
lytic replication. The relative association of all EBV transcripts
with SM was measured as it was with P3HR1-ZHT cells. Ly-
sates from B95-8-ZHT cells harvested 48 h after induction
were immunoprecipitated with anti-SM or PI serum and ana-
lyzed by qRT-PCR. The total amount of EBV RNAs isolated
in the B95-8 SM IPs was much greater than that observed in
P3HR1 cells and approximately 55 times greater than that in
the control IPs. This difference may reflect higher expression
of lytic genes in B95-8-ZHT cells. Nevertheless, a hierarchy of
association with SM was again observed among the various
EBV transcripts (Fig. 5 and Table 3). The enrichment was as
much as 37-fold over the mean enrichment, which, as noted,
was already 55-fold, whereas some transcripts, such as BALF2,
did not appear to associate significantly with SM and were
present at levels far below the mean enrichment. Of the seven
B95-8 transcripts most highly associated with SM, five were
also among the most highly SM-associated P3HR1 mRNAs,
again suggesting that transcript-specific properties determine
affinity for SM in vivo. These five transcripts were BFRF3,
BDLF3, BBRF3, BBRF2, and BTRF1 (Tables 2 and 3).
A comparison of the absolute levels of B95-8 transcripts with
the likelihood of association with SM in the SM immunopre-
cipitate was performed (Fig. 5B). Transcripts whose absolute
CT levels in the qRT-PCR measurement varied by as much as
5 CT units (approximately 30-fold difference) were highly rep-
resented in the SM IPs. Thus, the results again indicated that
preferential association with SM was not simply due to the
greater abundance of some transcripts.
The qRT-PCR array results were verified for representative
genes by Northern blotting, as was done with P3HR1-ZHT
lysates (Fig. 5C). The three genes BFRF3, BBRF3 (highly
SM-associated), and BALF2 (less SM associated) were present
in the total induced RNA population at similar levels (8- to
15-fold over uninduced) but were immunoprecipitated by SM
at significantly different levels (3.5-fold in the case of BALF2
versus 38- and 60-fold over control IPs in the cases of BBRF3
and BFRF3).
SM exhibits sequence-specific binding to EBV transcripts in
vitro. The finding that SM associated preferentially with cer-
tain EBV transcripts led us to ask whether SM bound more
avidly to specific sites within such transcripts. RNA binding
proteins that bind RNA directly can be shown to contact RNA
using a UV cross-linking and label transfer assay. We had
previously shown that SM in cell lysates could be labeled by
incubation and UV cross-linking to [32P]rUTP-labeled RNA
A.
B.
FIG. 4. Northern blot analysis of SM-enriched and unenriched
EBV RNAs. (A) RNA from mock-induced P3HR1-ZHT cells, in-
duced cells, PI IP, and SM IP were analyzed by Northern blotting for
BFRF3 and BBRF3 (identified as SM associated by qRT-PCR) or
BALF2 (non-SM enriched). The relative amounts of RNA were quan-
titated by phosphorimager measurement and are shown below the
lanes. IgG, immunoglobulin G. (B) The amounts of SM present in the
total cell lysate from uninduced (U) and induced (I) P3HR1-ZHT
cells, input lysate (Input), the control IP (IgG), and SM IP (SM) were
measured by immunoblotting with anti-SM antibody; 1% of input
lysate and 15% of the IP from cells are shown.
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transcripts in vitro (46). RNase hydrolysis of non-cross-linked
nucleotides and IP of SM, followed by SDS-PAGE and auto-
radiography, allowed the visualization of labeled SM protein.
In order to compare the relative abilities of regions of BFRF3
mRNA to bind SM, in vitro-labeled transcripts corresponding
to four segments of the entire BFRF3 gene comprised of 190,
205, 199, and 178 nt spanning the 5 UTR, coding regions, and
3 UTR of BFRF3 were generated by transcription with T7
RNA polymerase. In addition, full-length BFRF3 transcript
and antisense BFRF3 transcripts were synthesized. The integ-
rity and size of each radiolabeled transcript was verified by
polyacrylamide gel electrophoresis, and each transcript was
purified by excision and elution from the gel (Fig. 6A). Inter-
estingly, antisense BFRF3 did not cross-link to SM protein,
whereas full-length BFRF3 transcript strongly labeled SM pro-
tein under identical conditions, suggesting that BFRF3 RNA
contains specific sequences or secondary-structure elements
that contact SM protein (Fig. 6B). Further, analysis of the four
subclones of BFRF3 revealed that the first 190 nt of the tran-
script, which includes the 5 UTR, bound most strongly to SM.
While there was some binding of the second quarter (Q2) of
the BFRF3 transcript, there was virtually no binding by Q3 and
Q4 of the BFRF3 transcript (Fig. 6C).
A similar analysis was performed with the BDLF3 transcript,
which was identified as strongly SM associated in both P3HR1
and B95-8 cells (Fig. 7A). Full-length BDLF3 transcript exhib-
ited strong binding, whereas the antisense transcript again did
not exhibit significant label transfer to SM. In the case of
BDLF3, both Q1 and Q4 of the transcript exhibited greater
label transfer to SM than did Q2 and Q3 of the BDLF3 tran-
script. A fainter band that migrated at approximately the same
mobility as SM, which was also present in lysates lacking SM
(data not shown) and likely represents a cellular RNA binding
protein, was also detected in these experiments. Thus, both
BDLF3 and BFRF3 transcripts exhibited specific interactions
with SM in vitro, and these interactions appeared to map to
specific regions of each transcript. A similar analysis was per-
formed to assess the in vitro binding of BALF2 RNA, which
did not strongly associate with SM in vivo. As shown in Fig. 7B,
BALF2 RNA did not bind appreciably to SM compared to
BFRF3 RNA, consistent with the in vivo binding data, in which
BALF2 mRNA was not overrepresented in SM immunopre-
cipitates.
SM binding affinity in vitro and in vivo correlates with
enhanced RNA accumulation in response to SM. The findings
that sequences in highly SM-associated mRNAs, such as
BFRF3 and BDLF3, contained sequences that cross-linked to
SM in vitro suggested that these sequences could act as SM
TABLE 3. EBV transcripts highly enriched in SM











BDLF3 40 30.04 9.96 5.23 37.5
BNLF2b 40 30.13 9.87 5.14 35.3
BBRF3 34.44 27.51 6.93 1.95 3.9
BFRF3 32.66 25.2 7.46 1.88 3.7
BGLF2 33.98 26.69 7.29 1.86 3.6
BTRF1 35.76 28.93 6.83 1.61 3.1
BBRF2 34.44 27.51 6.93 1.55 2.9
BALF2 31.66 30.26 1.4 4.30 0.05
a The CT values from qRT-PCR of RNAs isolated from control IPs and SM
IPs and the CT are shown for the transcripts most highly overrepresented in the
SM IP. The values for BALF2, a transcript that was underrepresented in the SM
IP, are also shown for comparison. Enrichment in the SM IP relative to the mean
enrichment for all mRNAs in the IP is shown as CT and as enrichment.
FIG. 5. EBV RNAs associated with SM in B95-8 cells. (A) Enrich-
ment of each EBV transcript (the amount in SM IP versus PI IP)
compared to the mean enrichment for all transcripts in the SM IP was
calculated and plotted on the logarithmic y axis. Each EBV mRNA is
represented by a bar on the x axis. (B) Scatter plot of the relative
enrichment of each transcript in the SM IP versus the mean enrich-
ment for all transcripts (CT; y axis) versus the abundance of each
transcript (CT; x axis). The area highlighted in gray contains those
transcripts most highly enriched in the SM IP. (C) RNAs from mock-
induced B95-8ZHT cells, induced cells, PI IP, and SM IP were ana-
lyzed by Northern blotting for BFRF3 and BBRF3 (identified as SM
associated by qRT-PCR) or BALF2 (non-SM enriched). The relative
amounts of RNA were quantitated by phosphorimager measurement
and are shown below the lanes.
11640 HAN ET AL. J. VIROL.
response elements. In order to ask whether the presence of a
sequence with high affinity for SM could confer increased re-
sponsiveness to SM on a heterologous mRNA, we tested the
effect of fusing different BFRF3 subclones to the 5 UTR of a
reporter gene. The first 190 nt and the last 178 nt of the BFRF3
gene were each fused to the 5 terminus of the luciferase gene
in the pGL3 reporter plasmid. Each construct was transfected
in HeLa cells with either empty vector or the SM expression
plasmid. Accumulation of luciferase mRNA from each fusion
gene in the nucleus and cytoplasm was then measured by
Northern blotting. In the presence of SM, the levels of luciferase
mRNA fused to BFRF3 Q1 were higher than those of the BFRF3
Q4 fusion, particularly in the cytoplasm (Fig. 8A).
This result indicated that the presence of BFRF3 Q1 se-
quence that exhibited high affinity for SM in vitro conferred
increased accumulation in the presence of SM. One would
therefore expect that this RNA would also accumulate to
greater levels in the presence of SM than BFRF3 Q4, which
bound SM with less affinity in vitro. We therefore transfected
either BFRF3 Q1 or BFRF3 Q4 transcribed from a CMV
promoter along with SM plasmid or empty vector and com-
pared the accumulation of each corresponding BFRF3 RNA in
the presence or absence of SM. As predicted, the BFRF3 Q1
RNA accumulated to significantly higher levels than BFRF3
Q4 RNA when SM was present (Fig. 8B).
In order to determine whether the differences between these
two RNA sequences in enhancement by SM correlated with
SM association in vivo, as might be expected based on the in
vitro cross-linking results, we measured the amounts of BFRF3
Q1 versus BFRF3 Q4 RNA immunoprecipitable with SM.
Full-length BFRF3, BFRF3 Q1, or BFRF3 Q4 plasmid was
transfected along with SM plasmid, and RNA was isolated
from SM immunoprecipitates, as was done from P3HR1-ZHT
cells. When the SM-associated RNAs were measured by
Northern blotting, it was clear that BFRF3 Q1 was more highly
associated with SM. It should be noted that since SM enhances
the accumulation of BFRF3 Q1 more than accumulation of
BFRF3 Q4, the total amount of BFRF3 Q4 RNA was signif-
icantly less than BFRF3 Q1 or full-length BFRF3 RNA. Nev-
ertheless, as can be seen in Fig. 8C, the percentage of BFRF3
Q1 RNA or full-length BFRF3 RNA found in association with
SM was greater than that of BFRF3 Q4 RNA. In order to
ensure that SM was recovered with equal efficiency in each IP,
the amount of SM in each input lysate and each IP was quan-
titated by immunoblotting (Fig. 8C, bottom).
DISCUSSION
One of the current models for the mechanism of action of
SM and its homologs in other herpesviruses, such as HSV-1
ICP27, HCMV UL69, and KSHV ORF57 protein/Mta, postu-
lates that these proteins bind to intronless viral mRNAs and,
by binding to one or more cellular nuclear export factors,
facilitate the export of viral RNAs (for a review, see reference
38). A central aspect of this model is that SM and its homologs
compensate for the lack of export factor recruitment that nor-
mally occurs concomitant with splicing of intron-containing
genes (22, 32, 48). However, a basic question that is not ad-
FIG. 6. In vitro binding of SM to BFRF3 RNA. (A) In vitro-
transcribed and [32P]UTP-labeled RNA corresponding to four quar-
ters (qtr) of the BFRF3 mRNA, full-length mRNA, and antisense
mRNA were purified by urea-PAGE electrophoresis. (B) Radiola-
beled BFRF3 transcripts or antisense BFRF3 transcripts (AS-BFRF3)
were incubated with lysates from cells transfected with empty vector
(C) or SM as shown above each panel and cross-linked with UV light.
RNase-treated samples were immunoprecipitated with either PI serum
(PI) or anti-SM antibody (Ab), electrophoresed, and analyzed by au-
toradiography. (C) Transcripts from each quarter of BFRF3 were
incubated with SM lysate and analyzed as for panel B.
FIG. 7. In vitro binding of SM to BDLF3 RNA. (A) Full-length
BDLF3 RNA, antisense BDLF3, or transcripts from four quarters
(qtr) of the BDLF3 gene were analyzed for binding to SM by in vitro
photo-cross-linking and label transfer assay. A control reaction per-
formed in parallel without UV cross-linking (no X-link) is also shown.
(B) Transcripts from Q1 of BFRF3 or the corresponding region of
BALF2 were incubated with SM lysate (SM) in duplicate or mock-
transfected lysate (C) and analyzed as for panel A.
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dressed by such models is whether RNA-specific binding oc-
curs and whether it is required for the functions of these
proteins.
While much evidence exists for the ability of EBV SM,
HSV-1 ICP27, HCMV UL69, and KSHV ORF57/Mta proteins
to bind RNA, relatively little is known about the target spec-
ificity of these interactions, and the mechanism by which these
proteins bind to specific viral RNAs or RNA motifs remains
poorly characterized (4, 9, 17, 25, 33, 43). HSV ICP27 has been
shown to associate with seven intronless HSV transcripts, but
not with two intron-containing HSV transcripts, during lytic
HSV infection (37). ICP27 was also shown to associate with 31
HSV RNAs in a yeast three-hybrid assay (41). In this study, the
only identified characteristic of RNAs binding to ICP27 was
the presence of multiple G nucleotide repeats. Aside from the
suggestion that poly(G) sequences may increase ICP27 inter-
action, which is consistent with a previous study comparing
ICP27 binding to poly(G) and poly(U) (25), there was no
additional characterization of the relative affinities of various
RNAs for ICP27. More recently, systematic evolution of li-
gands by exponential enrichment has been used to define a
potential RNA motif targeted by herpesvirus saimiri ORF57
protein (9). Repetitive selection with oligonucleotide libraries
identified GAAGRG as a potential ORF57 protein binding
site. The motif was found in multiple herpesvirus saimiri
ORFs, and deletion of the motif from a herpesvirus saimiri
RNA led to loss of ORF57 protein binding.
In the case of EBV SM, very little specific binding to RNA
targets has been demonstrable. An arginine-rich region of 33
amino acids has been identified as an RNA binding region in
SM (17). This region does not strongly resemble classic RNA
binding protein motifs, such as RGG boxes, KH domains, or
RRM motifs. However, it contains two RS dipeptides and
three other arginine residues. In vitro, no target-specific bind-
ing could be demonstrated using a peptide containing this
motif (17). Limited comparisons of the affinity of SM for het-
erologous reporter gene RNAs suggested that SM bound
equally well to luciferase and chloramphenicol acetyltrans-
ferase despite having markedly greater effects on chloram-
phenicol acetyltransferase RNA accumulation (33). Attempts
to demonstrate site-specific RNA binding by in vitro cross-
linking of SM to RNA revealed some preferential binding, but
an ability to bind all the RNAs tested to some degree was
observed (46). Gene-specific activation of expression despite
apparently nonselective RNA binding by SM has been ex-
plained as possibly due to inherent differences in target tran-
scripts (17, 33). For example, SM might bind nonspecifically to
all RNAs but only affect the expression of those RNAs that are
unstable or incapable of independent nuclear export. Alterna-
tively, SM might act in a manner similar to that of cellular
RNA binding proteins that have broad RNA binding proper-
ties yet achieve extremely specific effects on target RNAs. SR
proteins that bind to short, degenerate sequences and
hnRNPs, which have both nonspecific and specific RNA bind-
ing properties, are classic examples of such RNA binding pro-
teins that exert gene-specific effects on alternative splicing.
Such specific effects are achieved by combinatorial effects, con-
text-dependent binding, and protein-protein interactions (40).
It is in this context that we investigated whether SM exhibits
any preferential association with EBV RNAs during the course
of lytic replication. In the current study, we chose to analyze
SM-RNA interactions without UV cross-linking, under rela-
tively gentle isolation conditions, in an attempt to preserve
physiologic interactions. Overall, it is clear that there are large
differences in the affinities of various RNAs for SM despite the
fact that under the conditions used in these experiments, SM
associated with the majority of EBV mRNAs.
While the abundance of an RNA species would be expected
to affect the percentage found complexed with SM if RNA
binding activity were nonspecific, it is clear that the extent to
FIG. 8. Differential binding of BFRF3 subclones to SM in vivo and
activity as an SM response element. (A) Plasmids in which BFRF3 Q1
or BFRF3 Q4 was fused upstream of the luciferase (luc) coding se-
quence in a reporter vector were cotransfected with either vector or
SM expression plasmid. RNA was isolated from both the nuclei
(N) and cytoplasm (C) of transfected cells and analyzed by Northern
blotting with luciferase probe. (B) BFRF3 Q1 and BFRF3 Q4 plasmids
were transfected with either vector or SM plasmid, and RNA was
analyzed by Northern blotting with BFRF3 probe. (C) Cells were
transfected with SM and either BFRF3 Q1, BFRF3 Q4, or full-length
BFRF3 plasmid (F.L.). RNA was isolated from total cell lysate (input
RNA) or from SM immunoprecipitates (SM-IP-RNA) and analyzed by
Northern blotting with BFRF3 probe. The amounts of SM in the input
lysate and in each immunoprecipitate (SM IP) were measured by
immunoblotting and are shown below.
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which an RNA is associated with SM is not simply dependent
on its abundance. It is likely, however, that the timing of the
experiment, which was chosen to maximize the number of lytic
RNAs that might be detected, affected the representation of
RNAs that were detected in association with SM. These data
therefore indicate that while SM does associate with a large
number of RNAs in vivo, a hierarchy of affinities for SM exists
among the various RNAs. Thus, it is unlikely that SM binds to
or affects only RNAs that contain a critical response element,
in the manner of human immunodeficiency virus Rev.
One caveat in our experiment is that the qRT-PCR primers
were directed against individual ORFs. Hence, we do not know
how ORF length, 3 or 5 UTR length, or the presence of
multiple SM binding regions affect our quantitation. We there-
fore used ranking-based statistics (44) to identify ORFs that
are encoded by mRNAs of as yet unspecified size that were
bound by SM.
The finding that two of the most highly SM-associated RNAs
in both P3HR1 and B95-8 cells exhibit region-specific binding
to SM in vitro and in vivo suggests that binding of at least some
RNAs to SM may be highly sequence or structure specific.
Significantly, SM binding to these regions was correlated with
the ability to enhance expression, suggesting that the specificity
of SM action is mediated at least in part by binding specificity.
Preferential binding to the 5 and 3 UTRs, albeit of only two
transcripts, is similar to the behavior of other RNA regulatory
proteins, such as eIF4E, which bind to so-called USER codes
in the 5 and 3 UTRs of target mRNAs (10–12). Such USER
codes consist of long, highly structured sequences, as well as
relatively short (40-nt) sequences in the case of eIF4E. It is
tempting to speculate that SM and its herpesvirus homologs
may perform coordinate regulation of transcripts as an RNA
regulon, as proposed by Keene and Tenenbaum (20). In this
model, multiple transcripts may be regulated as a posttran-
scriptional operon, allowing a protein that binds to common
elements in the UTRs of target genes to perform coordinated
functions, such as nuclear export, on all such target mRNAs.
The utility of an RNA regulon in herpesvirus replication is
apparent when one considers the multitude of lytic transcripts
that must be stabilized, exported, and translated in an efficient
manner in a limited time. Whether one or more specific SM
response elements are present in EBV transcripts, and possibly
cellular transcripts, remains to be experimentally confirmed.
There is no obvious homology between the 5 UTRs of BFRF3
and BDLF3, nor is there an obvious bias in the nucleotide
compositions of these regions. Further mapping of SM binding
by in vitro cross-linking experiments such as the ones described
here may allow the definition of one or more minimal binding
sites. However, by analogy to SR proteins, which bind to de-
generate consensus sequences and exhibit both general and
specific RNA binding, definition of SM target specificity by
bioinformatics analysis alone is unlikely to be successful, and
further biochemical characterization of SM RNA interactions
and definition of the crystal structure of SM and its homologs
may be required (16). The identification of transcripts that are
highly associated with SM in vivo should allow further charac-
terization of specific elements involved in coordinate posttran-
scriptional regulation by SM.
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